Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M
Clinical trial NCT03452592 · TERMINATED
Trial details
- NCT number
- NCT03452592
- Sponsor
- Allist Pharmaceuticals, Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-30
- Primary completion
- 2021-04-21
- Enrollment
- 220
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.